Dr. Roland L. Chu
Claim this profileChildren's Hospital of Michigan
Area of expertise
Neuroblastoma
Roland L. Chu has run 4 trials for Neuroblastoma. Some of their research focus areas include:
Ganglioneuroblastoma
Roland L. Chu has run 3 trials for Ganglioneuroblastoma. Some of their research focus areas include:
Affiliated Hospitals
Children's Hospital Of Michigan
Wayne State University/Karmanos Cancer Institute
Clinical Trials Roland L. Chu is currently running
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting
2 awards
Phase 3
26 criteria
Lorlatinib + Standard Therapy
for Neuroblastoma
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Recruiting
2 awards
Phase 3
22 criteria
More about Roland L. Chu
Clinical Trial Related
8 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Roland L. Chu has experience with
- Etoposide
- Cyclophosphamide
- Carboplatin
- Laboratory Biomarker Analysis
- Irinotecan Hydrochloride
- Unlicensed CBU
Breakdown of trials Roland L. Chu has run
Neuroblastoma
Ganglioneuroblastoma
Infusion Reaction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Roland L. Chu specialize in?
Roland L. Chu focuses on Neuroblastoma and Ganglioneuroblastoma. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are MYC positive.
Is Roland L. Chu currently recruiting for clinical trials?
Yes, Roland L. Chu is currently recruiting for 3 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Roland L. Chu has studied deeply?
Yes, Roland L. Chu has studied treatments such as Etoposide, Cyclophosphamide, Carboplatin.
What is the best way to schedule an appointment with Roland L. Chu?
Apply for one of the trials that Roland L. Chu is conducting.
What is the office address of Roland L. Chu?
The office of Roland L. Chu is located at: Children's Hospital of Michigan, Detroit, Michigan 48201 United States. This is the address for their practice at the Children's Hospital of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.